Alzheimer’s Association Chief Public Policy Officer Robert Egge and Senior Director of Medical Scientific Relations, Dr. Claire Sexton, will provide an update on lecanemab, the anti-amyloid treatment just approved by the FDA. They will review additional details about the drug and potential side effects and benefits. The conversation will also address next steps around access to the treatment.
Additional Resources:
-Learn more about treatments, questions for your doctor and more at https://www.alz.org/alzheimers-dementia/treatments.
-Ask Congress to Ensure Access to FDA-Approved Alzheimer’s Treatments. The Centers for Medicare & Medicaid Services (CMS) is blocking coverage of FDA-approved treatments targeting amyloid for Alzheimer’s. Join us in asking Congress to call on CMS to change this decision. Visit https://p2a.co/z1V1Wgz to take action for those living with Alzheimer’s.
-Alzheimer’s Association TrialMatch® connects individuals living with Alzheimer’s, caregivers and healthy volunteers to clinical trials that may advance Alzheimer’s research. Visit https://www.alz.org/trialmatch to learn more.
-Connect with our 24/7 Helpline at 1-800-272-3900. Through this free service, specialists and master’s-level clinicians offer confidential support and information to people living with dementia, caregivers, families and the public.
-Online education about Alzheimer’s, caregiving, managing money, healthy living, and more is available at https://www.alz.org/education.
-Local resources and support can also be found at https://www.communityresourcefinder.org and you can connect with others by visiting our free online community, https://www.alzconnected.org.
-Visit https://www.alz.org/alztalks to register for upcoming ALZ Talks webinars.
